ZTS 2026Q2 Earnings Preview

Timing note: Zoetis is scheduled to report before the U.S. market opens on Thursday, August 6, 2026, with its conference call at 8:30 a.m. ET. Given today’s date, the report is due today, not tomorrow.

Executive view

Zoetis enters Q2 with expectations substantially reset after a severe Q1 disappointment. The central issue is no longer whether the company can produce its historical high-single-digit growth; it is whether the deterioration in U.S. companion animal has stabilized enough to support management’s already-lowered 2026 guidance.

The Street is looking for approximately:

Those headline numbers matter, but the stock is more likely to trade on:

  1. The sequential trajectory in U.S. companion animal
  2. Whether dermatology and Simparica are stabilizing
  3. Evidence that Librela has reached a floor
  4. The credibility of the full-year guidance
  5. How much earnings support is coming from genuine operations versus cost reductions and a lower share count

The bar is low, but so is investor confidence.


The setup: a major credibility reset after Q1

Q1 revenue was $2.26 billion, up 3% reported but flat organically, with adjusted net income growing just 1% organically. The apparent consolidated stability masked a sharp geographic divergence:

Q1 2026 metric Organic operational growth
U.S. revenue -8%
U.S. companion animal -11%
International revenue +10%
Global companion animal -4%
Global livestock +12%

Even the International result requires context. Roughly $100 million of sales shifted into Q1 because of Zoetis’ fiscal-year alignment and related timing effects. Management said global organic revenue would have declined approximately 5% excluding that shift.

The company cut its 2026 outlook to:

Management’s guidance assumes that weak clinic traffic, consumer price sensitivity and heightened competition persist, but do not materially worsen.

That assumption is the main issue investors need Q2 to validate.


What investors should watch

1. U.S. companion animal: stabilization matters more than growth

U.S. companion animal fell 11% in Q1 as several pressures converged:

Management argued that distributor inventories ended Q1 at the low end of their normalized range and did not build a restocking recovery into guidance. That creates an important test in Q2.

A credible stabilization would likely require:

A continued high-single- or double-digit decline would challenge the full-year guide, even with easier comparisons later in 2026.


2. Dermatology is probably the most important franchise readout

Global key dermatology revenue declined 11% in Q1 to $347 million, including a 13% U.S. decline. Apoquel was hit by lower-cost alternatives and prolonged promotional activity, while Cytopoint held up better because competitive switching was relatively limited.

Investors should focus on:

Zoetis has said it does not intend to compete primarily through lower list prices. Instead, it is using targeted promotions, portfolio programs and pet-owner affordability initiatives. Q2 should reveal whether that approach is enough in a market where price has become a more important prescribing and purchasing consideration.

A smaller decline accompanied by stable patient share would be constructive. Further deterioration would suggest that Q1 was not merely a temporary adjustment but a more durable change in franchise economics.


3. Simparica needs to confirm management’s stabilization narrative

The global Simparica franchise declined 1% in Q1, with Simparica Trio down 1%. In the U.S., the franchise declined 8%, including an 8% decline for Trio.

Management nevertheless highlighted two encouraging indicators:

The challenge is that the triple-combination category is no longer expanding fast enough to offset competitive share pressure. Alternative-channel growth has also slowed from roughly 25%-30% historically to around 10%, with prescription denials contributing to the slowdown.

Key Q2 questions include:

A return to modest global growth would support management’s view that the franchise is stabilizing. Another material U.S. decline combined with slowing International growth would be more concerning.


4. Librela: look for a floor, not a rapid recovery

Librela remains an important sentiment driver despite being smaller than dermatology or Simparica.

Q1 Librela sales were:

Management said U.S. Librela revenue increased sequentially for the first time in six quarters and that patient share had been stable since the second half of 2025. It also believes education, specialist engagement and supportive benefit-risk assessments are improving veterinary confidence.

The immediate hurdle is modest: investors mainly need evidence that sales and patient starts are no longer deteriorating.

Watch for:

Stable-to-improving U.S. sales would be a positive. Renewed sequential weakness or reduced confidence in the product’s recovery would likely overshadow a headline EPS beat.


5. Livestock and International must remain reliable offsets

Livestock was Q1’s clearest source of operating strength, growing 12% organically. Performance was broad-based across cattle, swine, poultry and fish, supported by favorable producer economics, disease-related vaccine demand and improved supply.

Management expects livestock to grow in the mid- to high-single digits for the full year. Investors should look for:

International performance also warrants scrutiny. Emerging markets continue to offer attractive medicalization and geographic-expansion opportunities, but developed markets are experiencing some of the same companion-animal pressures seen in the U.S.

The cleanest result would be sustained livestock growth and healthy emerging-market companion-animal growth, without another major timing benefit.


6. Guidance quality is more important than a simple reiteration

The 2%-5% organic revenue guide includes roughly 200-250 basis points of benefit from the fiscal-year alignment. This makes the underlying trajectory weaker than the headline range may initially suggest and creates a difficult comparison entering 2027.

Management needs to explain:

A bare guidance reiteration may not be enough. Investors will want a credible bridge from Q1’s weakness to the implied improvement over the rest of the year.

A reduction in the revenue range would be particularly damaging because the existing outlook was issued only one quarter ago and already reflects a cautious environment.


7. Margins and EPS: distinguish operating progress from financial engineering

Zoetis reacted to Q1 weakness with a comprehensive cost and productivity program. Adjusted gross margin was 71.8% in Q1 and improved approximately 140 basis points excluding currency, helped by pricing and lower manufacturing costs.

Cost execution can protect earnings, but investors should ask whether it is masking continuing pressure in the company’s highest-margin companion-animal franchises. Faster livestock growth and weaker premium companion-animal products create an unfavorable mix effect.

The share count is another consideration. Q1 adjusted net income grew only 1% organically, while adjusted EPS grew 7%, helped by repurchases. Zoetis repurchased approximately $612 million of stock in Q1 after issuing $2 billion of low-coupon convertible debt in December 2025, with most of the net proceeds ultimately used for buybacks.

Useful Q2 metrics include:

An EPS beat driven primarily by a lower share count or unusually low spending would be lower quality than one supported by improving revenue and gross profit.


Bull, base and bear interpretations

Bull case

Given the depressed valuation and sentiment, evidence that the business has simply stopped getting worse could drive a meaningful relief reaction.

Base case

This would support the shares but may not be enough for a durable rerating without clearer evidence of returning organic growth.

Bear case

That outcome would suggest the company is facing a multi-year reset rather than a temporary soft patch.


Valuation and stock setup

ZTS closed at $74.41 on August 5, down approximately:

At that price, the stock trades at roughly 10.7 times the midpoint of management’s 2026 adjusted-EPS guidance.

That is a dramatically lower valuation than investors historically assigned Zoetis, but the debate is whether current earnings represent a trough or whether the company’s premium growth model has structurally weakened.

The depressed multiple lowers the threshold for a positive reaction, but it does not eliminate downside if guidance credibility deteriorates further.


Questions management needs to answer

  1. How did U.S. companion-animal end-market demand progress month by month during Q2?
  2. Are distributor and retailer inventories now fully aligned with end-market demand?
  3. Did Apoquel patient share stabilize, and what net-price pressure is Zoetis accepting to protect the franchise?
  4. Did Simparica Trio’s sequential share recovery continue?
  5. Is Librela growing sequentially in the U.S., and when does management expect year-over-year growth?
  6. How much of second-half revenue growth depends on easier comparisons and fiscal-year-alignment effects?
  7. What is assumed for U.S. companion-animal growth in the full-year guide?
  8. How much of adjusted EPS growth is expected from operating income versus the lower share count?
  9. What annualized savings does the productivity program target, and is R&D investment being preserved?
  10. How should investors think about the 200-250-basis-point alignment benefit reversing as a comparison issue in 2027?

Bottom line

This is fundamentally a stabilization report.

A modest earnings beat will not be sufficient if dermatology, Simparica and Librela continue to deteriorate. Conversely, Zoetis does not need to demonstrate an immediate return to historical growth to produce a favorable reaction. Clear evidence that U.S. companion animal has bottomed, combined with intact guidance and continued livestock strength, could be enough given the stock’s severe decline and low expectations.

The highest-signal indicators will be:

  1. U.S. companion-animal growth
  2. Dermatology patient share and net pricing
  3. Simparica Trio share
  4. Sequential U.S. Librela sales
  5. The operational assumptions supporting full-year guidance

The key investment question is shifting from “How bad was Q1?” to “Was Q1 the trough?”